Citigroup
CODX

Citigroup’s Co-Diagnostics CODX Stock Holding History

Citigroup’s Portfolio CODX Stock Details CODX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1
Closed -$2 – 5802
2026
Q1 		$2 Buy
+1
New +$3 ﹤0.01% 5826
2025
Q4 		– Sell
-49
Closed -$501 – 6126
2025
Q3 		$501 Sell
49
-130
-73% -$1.21K ﹤0.01% 5707
2025
Q2 		$1.51K Buy
179
+169
+1,690% +$1.58K ﹤0.01% 5378
2025
Q1 		$91 Buy
+10
New +$191 ﹤0.01% 5439
2021
Q3 		– Sell
-3
Closed -$1K – 5824
2021
Q2 		$1K Sell
3
-71
-96% -$18.3K ﹤0.01% 6024
2021
Q1 		$21K Sell
74
-129
-64% -$51.5K ﹤0.01% 5210
2020
Q4 		$57K Buy
203
+34
+20% +$12.6K ﹤0.01% 5942
2020
Q3 		$69K Sell
169
-212
-56% -$109K ﹤0.01% 5370
2020
Q2 		$221K Buy
+381
New +$174K ﹤0.01% 4942

Other funds holding CODX

AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PAG
Private Advisory Group Redmond, Washington $1.85B AUM 50.66% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Citigroup's CODX Position: Q2 2026 in Review

Citigroup sold out of Co-Diagnostics (CODX) in Q2 2026, closing a stake of 1 share — an estimated $2 sold.

Citigroup first reported a position in CODX in Q2 2020 and held it in 9 quarters. The position peaked at $221K in Q2 2020. 24 funds tracked by Wall St. Rank hold CODX as of Q2 2026.

  • Citigroup reported no remaining Co-Diagnostics position as of Q2 2026 after selling out during the quarter.
  • Citigroup sold 1 Co-Diagnostics share in Q2 2026, an estimated $2.
  • Citigroup first reported a position in Co-Diagnostics in Q2 2020 and held it in 9 quarters.
  • Citigroup's Co-Diagnostics position peaked at $221K in Q2 2020.
  • 24 funds tracked by Wall St. Rank held Co-Diagnostics as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.